BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the relaunch of its prescription dermatology and eye care products lines.
The prescription-strength products include: Acuicyn Eyelid & Eyelash Hygiene, Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel and Celacyn Scar Management Gel. In addition, Lasercyn Dermal Spray and Lasercyn Gel are available for over-the-counter use. These hypochlorous acid-based products were previously sold through a distributor to physicians, clinics and pharmacies. The products will now be available directly from Sonoma.
"We are excited to bring back these trusted products and expand our direct offerings for dermatology and eye care," said Amy Trombly, CEO of Sonoma. "These prescription products complement our over-the-counter product line in the U.S., allowing health care professionals and their patients multiple options for effective and safe eye care and scar management, as well as freedom from itch, pain and common skin irritations, including relief following ophthalmological and cosmetic procedures. These products are well-known and well-regarded by physicians across the country, and represent the versatile power of our Microcyn technology."
All products will be available December 9, 2024 and can be pre-ordered prior to that date. For more information or to place an order, contact our customer service department at 720-452-9690 or customerservice@sonomapharma.com.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at . For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals, Microcyn, Acuicyn, Epicyn, Levicyn, Celacyn and Lasercyn are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Follow us on LinkedIn:
Follow us on Instagram:
Follow us on Facebook:
SOURCE: Sonoma Pharmaceuticals, Inc.
